HbA1c is routinely used in the clinical laboratory to diagnose and monitor diabetes mellitus. Many methods have been standardized to provide precise and accurate results for normal patients. For the other common Hb variants, most of the methods are now relatively free of analytical interference.

In this webinar, Dr David Sacks and Dr. John Higgins, explains the clinical value of HbA1c in individual patient care; when an analytically correct result provides clinically misleading information due to red cell/hemoglobin lifespan. How should these patients be identified and managed so the best care can be provided to the patient? How can laboratory help?


Learning objectives

  • Identify components contributing to glycation rate of Hb to form HbA1c
  • Discuss which conditions can cause an artificial decrease/reduction in the levels of circulating HbA1c
  • Review which conditions should prevent the use of HbA1c for monitoring/diagnosing diabetic patients
  • Identify methods that indicate the presence of clinically significant hemoglobinopathies and/or thalassemia’s


David B. SACKS
Senior Investigator - Chief Clinical Chemistry Service - NIH
Associate Professor of Systems Biology Harvard Medical School; Associate Pathologist Massachusetts General Hospital

Do you have questions about this webinar?

Contact us